It is the patient’s combination of genetic risk coding (e.g. LRRK2-G2019S or SNCA-A53T) and non-coding variants that initially “set the stage” and determine which basecamp and mountain an individual will start ascending in their journey towards PD. This evidence concerns the gene LRRK2 and Parkinson disease.